Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prabotulinumtoxinA
- Development stage
- Approved
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PrabotulinumtoxinA is a 900 kDa botulinum toxin type A produced from fermentation of Clostridium botulinum. It blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This mechanism temporarily reduces muscle activity in the targeted area. It is primarily used for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) associated with corrugator and/or procerus muscle activity in adult patients.
- Brand names
- JeuveauNabotaNuceivaEvosyal
- Other names
- prabotulinumtoxinA-xvfs
02
Targets
GD3 (Ganglioside GD3)SNAP25 (Synaptosome-associated protein 25)SV2A (Synaptic vesicle glycoprotein 2A)
Beyond the preview
Go deeper on prabotulinumtoxinA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prabotulinumtoxinA.